CollPlant
A regenerative and aesthetic medicine company developing innovative 3D bioprinting technologies and products based on proprietary plant-derived recombinant human collagen (rhCollagen) for tissue regeneration, organ manufacturing, and medical aesthetics.
- CEO / Founder
- Yehiel Tal
- Team Size
- 51-200
- Stage
- Public company (NASDAQ: CLGN) with commercial bioink products available; multiple pipeline products in preclinical development including regenerative breast implants and photocurable dermal fillers; active partnerships with Stratasys and AbbVie; expanded North American commercial operations in 2025
- Total Funding
- $25.0M+
- Latest Round
- Registered Direct Offering ($2.0M, Feb 2026)
- Key Investors
- ["Pontifax","Docor International","Alpha Capital Partners","Ami Sagy"]
Technology & Products
Key Products
["Collink.3D® BioInks - First and only human collagen-based bioink line for 3D bioprinting","BioFlex - Ready-to-print rhCollagen-based kit for DLP bioprinting applications","Regenerative Breast Implants - 3D bioprinted commercial-sized (200cc) implants","Photocurable Dermal Fillers - Light-activated rhCollagen aesthetic treatments","rhCollagen Raw Material - Pure recombinant human collagen for biomedical applications","Tissue/Organ-on-a-Chip Systems - Alternative to animal testing models"]
Technological Advantage
Proprietary plant-based recombinant human Type I collagen production technology that provides mass-production scalability, batch-to-batch consistency, high purity, zero risk of human pathogen transmission, elimination of immune response compared to animal-derived collagen, and full biocompatibility with human tissue - enabling revolutionary applications in 3D bioprinting and regenerative medicine that were previously impossible.
Market & Competition
Target Customers
Medical device manufacturers, pharmaceutical companies, research institutions, aesthetic medicine practitioners, tissue engineering companies, and organizations seeking alternatives to animal testing in drug development and safety studies
Industry Verticals
["Regenerative Medicine","3D Bioprinting","Medical Aesthetics","Tissue Engineering","Medical Devices","Pharmaceutical Research","Orthopedics","Advanced Wound Care"]
Competitors
["CELLINK (BICO Group)","3D Systems (Allevi)","Advanced BioMatrix"]